Basilar Artery OcclusionBAOCHE-LCNCT07345702
Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct
An observational study of Basilar Artery Occlusion and Ischemic Stroke, run by Xuanwu Hospital, Beijing at 1 site in China.
Trial summary
This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Basilar Artery Occlusion, Ischemic Stroke, Large Core Infarct
- What is being tested?
- Endovascular Therapy
- Type of treatment
- Surgery or procedure
- How many people
- 518 participants
- Where
- 1 siteChina
- Study dates
- 31 Jan 2026to 31 Oct 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults (≥18 years) with imaging-confirmed acute vertebrobasilar occlusion and large-core infarction (pc-ASPECTS 0-5) treated within 7 days of symptom onset/last known well at participating centers in China. Patients are identified retrospectively from routine clinical practice and classified according to treatment received: endovascular therapy plus standard medical management versus standard medical management alone.
Who may be able to join
- Age ≥18 years, men or women.
- Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
- Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.
- Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.
Who cannot join
- Subjects with occlusions in both anterior and posterior circulation.
- CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
- Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset/last known well time, or missing major treatment information including whether EVT was performed).
- Baseline NIHSS score <6.
- Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
- Missing follow-up outcomes at 90 days.
- Any other condition judged by investigators to substantially affect analysis or interpretation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xuanwu Hospital
Beijing, Beijing Municipality, 100053
Chuanhui Li, 15210439828, lichuanhui@xwh.ccmu.edu.cn
About this study
Official title: Endovascular Versus Medical Therapy for Acute Large-Core Basilar Artery Occlusion: A Multicenter Retrospective Registry Study (BAOCHE-LC)
This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.
- Being tested
- Endovascular Therapy
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endovascular TherapyProcedure or surgery
Endovascular therapy performed as part of routine clinical care for acute basilar artery occlusion, including mechanical thrombectomy with stent retriever and/or aspiration. Rescue angioplasty and/or intracranial stenting may be used at the operator's discretion. Peri-procedural management and concomitant medical therapy follow local standard practice.
| Study group | Role | What they receive |
|---|---|---|
| Endovascular Therapy | Not described Receives: Procedure: Endovascular Therapy | |
| Best Medical Treatment Alone | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Patients Achieving mRS 0-3 at 90 Days
The modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Higher scores mean a worse outcome.
Measured: 90 days
Secondary outcomes (4)
Ordinal Shift analysis of mRS at 90 days
The modified Rankin scale (range, 0 [no symptoms] to 6 [death])
Measured: 90 days
Rate of All-Cause Mortality at 90 Days
Death from any cause within 90 days.
Measured: 90 days
Rate of Symptomatic Intracranial Hemorrhage
Measured: 24 (-2/+12) hours
Proportion of Patients Achieving mRS 0-3 at 1 year
The modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Higher scores mean a worse outcome.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start31 Jan 2026
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Basilar Artery OcclusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 518 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xuanwu Hospital, Beijing
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chuanhui Li, Xuanwu Hospital, Beijing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07345702
- Sponsor's protocol ID
- BAOCHE-LC
- Acronym
- BAOCHE-LC
- Status last verified
- Jan 2026
- First submitted
- 7 Jan 2026
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The study is proceeding.